Status:
COMPLETED
COVID-19 Antibody and Reinfection Study
Lead Sponsor:
Kaiser Permanente
Conditions:
COVID-19 Testing
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this study is to establish a cohort of Kaiser Permanente Colorado (KPCO) members who have and have not had COVID-19 infection for serial antibody testing and PCR testing to: 1. Quantify a...
Detailed Description
In this study, the Kaiser Permanente Colorado (KPCO) Institute for Health Research (IHR) will evaluate SARS-CoV-2 IgG antibody titers over time among individuals with evidence of prior infection, and ...
Eligibility Criteria
Inclusion
- Inclusion criteria are Kaiser Permanente Colorado health plan members, with a valid email address or phone number in the electronic health record and not on the Do Not Call List for research.
Exclusion
Key Trial Info
Start Date :
June 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
4235 Patients enrolled
Trial Details
Trial ID
NCT05365750
Start Date
June 15 2020
End Date
December 31 2024
Last Update
September 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente
Aurora, Colorado, United States, 80014